EULAV Asset Management Grows Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

EULAV Asset Management lifted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 12.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 131,000 shares of the biotechnology company's stock after buying an additional 15,000 shares during the quarter. EULAV Asset Management owned approximately 0.07% of BioMarin Pharmaceutical worth $9,208,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Primecap Management Co. CA boosted its holdings in shares of BioMarin Pharmaceutical by 0.4% in the 2nd quarter. Primecap Management Co. CA now owns 18,790,085 shares of the biotechnology company's stock valued at $1,546,988,000 after buying an additional 76,190 shares during the period. Vanguard Group Inc. grew its position in BioMarin Pharmaceutical by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 18,117,108 shares of the biotechnology company's stock worth $1,582,348,000 after purchasing an additional 67,046 shares during the last quarter. Avoro Capital Advisors LLC increased its stake in shares of BioMarin Pharmaceutical by 4.4% in the second quarter. Avoro Capital Advisors LLC now owns 4,557,416 shares of the biotechnology company's stock valued at $375,212,000 after purchasing an additional 192,416 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of BioMarin Pharmaceutical by 38.9% during the second quarter. Dimensional Fund Advisors LP now owns 1,034,457 shares of the biotechnology company's stock valued at $85,178,000 after buying an additional 289,953 shares during the last quarter. Finally, DNB Asset Management AS boosted its position in BioMarin Pharmaceutical by 17.7% during the 2nd quarter. DNB Asset Management AS now owns 1,021,054 shares of the biotechnology company's stock worth $84,063,000 after acquiring an additional 153,867 shares during the period. Institutional investors own 98.71% of the company's stock.

Analyst Ratings Changes

BMRN has been the topic of a number of research reports. Wedbush raised BioMarin Pharmaceutical to a "strong-buy" rating in a research note on Monday, November 4th. JPMorgan Chase & Co. reduced their target price on BioMarin Pharmaceutical from $110.00 to $109.00 and set an "overweight" rating for the company in a report on Wednesday, October 30th. Raymond James reaffirmed an "outperform" rating and set a $79.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday, October 10th. Wolfe Research assumed coverage on shares of BioMarin Pharmaceutical in a research note on Friday, November 15th. They set an "outperform" rating and a $95.00 target price for the company. Finally, Canaccord Genuity Group lowered their price target on shares of BioMarin Pharmaceutical from $93.00 to $84.00 and set a "hold" rating on the stock in a report on Wednesday, October 30th. Seven equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, BioMarin Pharmaceutical presently has a consensus rating of "Moderate Buy" and a consensus price target of $94.20.

BioMarin Pharmaceutical Trading Up 1.0 %

NASDAQ BMRN traded up $0.59 during trading hours on Wednesday, reaching $62.56. The company's stock had a trading volume of 1,245,536 shares, compared to its average volume of 1,829,197. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.27 and a quick ratio of 2.62. BioMarin Pharmaceutical Inc. has a 52 week low of $61.15 and a 52 week high of $99.56. The firm has a fifty day simple moving average of $69.53 and a 200-day simple moving average of $78.82. The stock has a market cap of $11.92 billion, a P/E ratio of 37.11, a P/E/G ratio of 0.63 and a beta of 0.31.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.78 by ($0.23). The firm had revenue of $746.00 million for the quarter, compared to the consensus estimate of $703.37 million. BioMarin Pharmaceutical had a return on equity of 8.53% and a net margin of 11.71%. The firm's revenue for the quarter was up 28.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.26 EPS. Equities analysts forecast that BioMarin Pharmaceutical Inc. will post 2.47 earnings per share for the current fiscal year.

Insider Activity

In other BioMarin Pharmaceutical news, EVP Charles Greg Guyer sold 5,278 shares of the business's stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $66.37, for a total transaction of $350,300.86. Following the completion of the sale, the executive vice president now owns 68,909 shares in the company, valued at approximately $4,573,490.33. The trade was a 7.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.85% of the stock is currently owned by company insiders.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.